Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

Autor:	Bekker, L.-G.1, Das, M.2 moupali.das@gilead.com, Karim, Q. Abdool3, Ahmed, K.4,5, Batting, J.1,6,7, Brumskine, W.8,9, Gill, K.1,7, Harkoo, I.10, Jaggernath, M.6, Kigozi, G.11, Kiwanuka, N.12, Kotze, P.13, Lebina, L.14,15, Louw, C. E.16, Malahleha, M.17, Manentsa, M.18, Mansoor, L. E.10, Moodley, D.10, Naicker, V.19, Naidoo, L.19
Zdroj:	New England Journal of Medicine. 10/3/2024, Vol. 391 Issue 13, p1179-1192. 14p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu